Cargando…

A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer’s disease

Successful disease modifying drug development for Alzheimer’s disease (AD) has hit a roadblock with the recent failures of amyloid-based therapies, highlighting the translational disconnect between preclinical animal models and clinical outcome. Although disease modifying therapies are the Holy Grai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geerts, Hugo, Roberts, Patrick, Spiros, Athan, Carr, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627142/ https://www.ncbi.nlm.nih.gov/pubmed/23596419 http://dx.doi.org/10.3389/fphar.2013.00047

Ejemplares similares

A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson’s Disease
por: Roberts, Patrick, et al.
Publicado: (2016)

A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance
por: Spiros, Athan, et al.
Publicado: (2014)

Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology
por: Geerts, Hugo, et al.
Publicado: (2015)

A biophysically realistic computer model of Alzheimer pathology to guide the development of symptomatic drugs
por: Roberts, Patrick D, et al.
Publicado: (2012)

Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model
por: Geerts, Hugo, et al.
Publicado: (2018)

Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action
por: Roberts, Patrick D, et al.
Publicado: (2012)

Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse
por: Spiros, Athan, et al.
Publicado: (2010)

Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach
por: Geerts, Hugo, et al.
Publicado: (2020)

Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
por: Lanctôt, Krista L., et al.
Publicado: (2017)

A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development
por: Spiros, Athan, et al.
Publicado: (2012)

F189. PERSONALIZED MEDICINE: ESTIMATING THE IMPACT OF GENOTYPES ON ANTIPSYCHOTIC EFFICACY USING A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH
por: Geerts, Hugo, et al.
Publicado: (2018)

Toward Predicting Impact of Common Genetic Variants on Schizophrenia Clinical Responses With Antipsychotics: A Quantitative System Pharmacology Study
por: Spiros, Athan, et al.
Publicado: (2021)

Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia
por: Ng, Kok Pin, et al.
Publicado: (2019)

Blinded Prospective Evaluation of Computer-Based Mechanistic Schizophrenia Disease Model for Predicting Drug Response
por: Geerts, Hugo, et al.
Publicado: (2012)

Dysfunctional mitochondrial processes contribute to energy perturbations in the brain and neuropsychiatric symptoms
por: Büttiker, Pascal, et al.
Publicado: (2023)

Large Sample Size Fallacy in Trials About Antipsychotics for Neuropsychiatric Symptoms in Dementia
por: Hulshof, Tessa A., et al.
Publicado: (2020)

Multipronged Attack of Stem Cell Therapy in Treating the Neurological and Neuropsychiatric Symptoms of Epilepsy
por: Sadanandan, Nadia, et al.
Publicado: (2021)

Strengths and Weaknesses of the Gray Mouse Lemur (Microcebus murinus) as a Model for the Behavioral and Psychological Symptoms and Neuropsychiatric Symptoms of Dementia
por: Pifferi, Fabien, et al.
Publicado: (2019)

Principles and management of neuropsychiatric symptoms in Alzheimer’s dementia
por: Nowrangi, Milap A, et al.
Publicado: (2015)

Neuropsychiatric Symptoms of Alzheimer's Disease and Caregiver Burden
por: Iravani, Behnam, et al.
Publicado: (2022)

Network Analysis of Neuropsychiatric Symptoms in Alzheimer’s Disease
por: Goodwin, Grace J., et al.
Publicado: (2023)

Network analysis of neuropsychiatric symptoms in Alzheimer’s disease
por: Goodwin, Grace J., et al.
Publicado: (2023)

Has the Time Come for Predictive Computer Modeling in CNS Drug Discovery and Development?
por: Geerts, H, et al.
Publicado: (2012)

A new paradigm shift in antithrombotic therapy
por: Pudusseri, Anita, et al.
Publicado: (2013)

Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer’s Disease and Related Disorders
por: David, Renaud, et al.
Publicado: (2010)

S221. QUANTITATIVE SYSTEMS PHARMACOLOGY AS AN ALTERNATIVE TO CHLORPROMAZINE EQUIVALENTS: PREDICTIVE VALIDATION FROM A CRIS DATABASE EXPERIMENT
por: Geerts, Hugo, et al.
Publicado: (2018)

Neuropsychiatric Disorders in Chronic Kidney Disease
por: Simões e Silva, Ana Cristina, et al.
Publicado: (2019)

Exploring the Multi–Target Neuroprotective Chemical Space of Benzofuran Scaffolds: A New Strategy in Drug Development for Alzheimer’s Disease
por: Cabrera-Pardo, Jaime R., et al.
Publicado: (2020)

Neuropsychiatric Symptoms in Posterior Cortical Atrophy and Alzheimer Disease
por: Suárez-González, Aida, et al.
Publicado: (2016)

Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease
por: Ng, Kok Pin, et al.
Publicado: (2017)

Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease
por: Schaffer Aguzzoli, Cristiano, et al.
Publicado: (2023)

Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer’s disease
por: Hall, James R, et al.
Publicado: (2015)

Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare
por: Kadra, Giouliana, et al.
Publicado: (2018)

The role of maternal obesity in the risk of neuropsychiatric disorders
por: Rivera, Heidi M., et al.
Publicado: (2015)

Editorial: New Paradigms in Neuroscience and Related Targets for Drug Discovery
por: Salomone, Salvatore
Publicado: (2020)

Efficacy of serious exergames in improving neuropsychiatric symptoms in neurocognitive disorders: Results of the X‐TORP cluster randomized trial
por: Robert, Philippe, et al.
Publicado: (2021)

Repurposing of Anti-Diabetic Agents as a New Opportunity to Alleviate Cognitive Impairment in Neurodegenerative and Neuropsychiatric Disorders
por: Chen, Qian, et al.
Publicado: (2021)

Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls
por: Yeoh, Jiann Wei, et al.
Publicado: (2014)

Editorial: Innovative pharmacometric approaches to inform drug development and clinical use
por: Garcia-Cremades, Maria, et al.
Publicado: (2023)

Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
por: Schenberg, Eduardo Ekman
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kvvj18j0n160lj800b3lm7k3ri